Thursday, July 9, 2026
🇺🇸 FDA

biotech · Ovarian Clear Cell Carcinoma · Tumors · LIXT

LIXTE BIOTECHNOLOGY HOLDINGS

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

LIXTE BIOTECHNOLOGY HOLDINGS patent portfolio — 26 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
East Setauket, USA HQ
2006 Founded
7 Employees
Public company Type
LIXT · NYSE Ticker
Company details
Status
Public
HQ
East Setauket, USA
Founded
2006
Employees
7
Programs
3
Drugs
3
Patents
26
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

LIXTE BIOTECHNOLOGY HOLDINGS patents

26 pharmaceutical patents indexed for LIXTE BIOTECHNOLOGY HOLDINGS. 0 expire within 24 months.

LIXTE BIOTECHNOLOGY HOLDINGS has 26 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

26 patents

Patent portfolio

  1. US 12343342

    Methods for treating soft tissue sarcoma

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11931354

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Expires Mon Mar 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11866444

    Oxabicycloheptane prodrugs

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11236102

    Oxabicycloheptane prodrugs

    Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10668062

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10618908

    Oxabicycloheptane prodrugs

    Expires Mon Apr 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10532050

    Formulations of oxabicycloheptanes and oxabicycloheptenes

    Expires Mon Jan 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10434100

    Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

    Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10413541

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

    Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10399993

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10364252

    Oxabicycloheptane prodrugs

    Expires Mon Jul 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10149847

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes

    Expires Mon Dec 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10023587

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Jul 12 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9994584

    Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9988394

    Oxabicycloheptane prodrugs

    Expires Mon May 31 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9833450

    Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders

    Expires Mon Nov 30 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9079917

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8822461

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Aug 28 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8541458

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Sep 19 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 8455688

    HDAC inhibitors

    Expires Mon May 30 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 8426444

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Apr 18 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 8329719

    Neuroprotective agents for the prevention and treatment of neurodegenerative diseases

    Expires Mon Dec 06 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 8227473

    Oxabicycloheptanes and oxabicycloheptenes, their preparation and use

    Expires Mon Jul 19 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 8143445

    HDAC inhibitors

    Expires Mon Mar 22 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 8058268

    Neuroprotective agents for the prevention and treatment of neurodegenerative diseases

    Expires Mon Nov 10 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7998957

    Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use

    Expires Mon Aug 11 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does LIXTE BIOTECHNOLOGY HOLDINGS have?

26 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do LIXTE BIOTECHNOLOGY HOLDINGS patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.